Rosuvastatin is additive to high-dose candesartan in slowing progression of experimental mesangioproliferative glomerulosclerosis

American Journal of Physiology - Renal Physiology

Volumn 294, Issue 4, 2008, Pages

  Krämer, Stephanie ^a   Kron, Susanne ^a   Wang Rosenke, Yingrui ^a   Loof, Tanja ^a   Khadzhynov, Dmytro ^a   Morgera, Stanislao ^a   Kawachi, Hiroshi ^b   Shimizu, Fujio ^b   Martini, Sebastian ^a   Neumayer, Hans H ^a   Peters, Harm ^a,c  

^a HUMBOLDT UNIVERSITY   (Germany)

^b NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

IgA nephropathy; Renal fibrosis; Transforming growth factor 1

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; CANDESARTAN; FIBRONECTIN; ROSUVASTATIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA1; BENZIMIDAZOLE DERIVATIVE; FLUOROBENZENE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRIMIDINE DERIVATIVE; SULFONAMIDE; TETRAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MEGADOSE; DRUG POTENTIATION; GLOMERULOSCLEROSIS; HISTOPATHOLOGY; IMMUNOGLOBULIN A NEPHROPATHY; MALE; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; RAT; RENAL PROTECTION; SYSTOLIC BLOOD PRESSURE; ANIMAL; DISEASE COURSE; DISEASE MODEL; DRUG COMBINATION; DRUG EFFECT; FOCAL GLOMERULOSCLEROSIS; GLOMERULUS; PATHOLOGY; WISTAR RAT;

ANIMALS; BENZIMIDAZOLES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FLUOROBENZENES; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY GLOMERULUS; MALE; PROTEINURIA; PYRIMIDINES; RATS; RATS, WISTAR; SULFONAMIDES; TETRAZOLES;

EID: 44949135069     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00148.2007     Document Type: Article

References (29)

1. Agarwal R, Curley TM. The role of statins in chronic kidney disease. Am J Med Sci 330: 69-81, 2005.
2. Baigent C, Landry M. Study of Heart and Renal Protection (SHARP). Kidney Int Suppl S207-S210, 2003.
3. Bianchi S, Bigazzi R, Caiazza A, Campese VM. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis 41: 565-570, 2003.
4. Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med 331: 1286-1292, 1994.
5. Calabro P, Yeh ETH. The pleotropic effects of statins. Curr Opin Cardiol 20: 541-546, 2005.
6. Eddy AA. Interstitial fibrosis in hypercholesterolemic rats: role of oxidation, matrix synthesis, and proteolytic cascades. Kidney Int 53: 1182-1189, 1998.
7. Floege J. Evidence-based recommendations for immunosuppression in IgA nephropathy: handle with caution. Nephrol Dial Transplant 18: 241-245, 2003.
8. Igarashi M, Hirata A, Yamaguchi H, Tsuchiya H, Ohnuma H, Tominaga M, Daimon M, Kato T. Candesartan inhibits carotid intimal thickening and ameliorates insulin resistance in balloon-injured diabetic rats. Hypertension 38: 1255-1259, 2001.
9. Julian BA, Novak J. IgA nephropathy: an update. Curr Opin Nephrol Hypertens 13: 171-179, 2004.
10. Klahr S, Schreiner G, Ichikawa I. The progression of renal disease. N Engl J Med 318: 1657-1666, 1988.
11. Krämer S, Loof T, Martini S, Rückert M, Wang Y, Böhler T, Shimizu F, Kawachi H, Neumayer HH, Peters H. Mycophenolate mofetil slows progression in anti-thy1-induced chronic renal fibrosis, but is not additive to a high dose of enalapril. Am J Physiol Renal Physiol 289: F359-F368, 2005.
12. Lee SK, Jin SY, Han DC, Hwang SD, Lee HB. Effects of delayed treatment with enalapril and/or lovastatin on the progression of glomerulosclerosis in 5/6 nephrectomized rats. Nephrol Dial Transplant 8: 1338-1343, 1993.
13. Mason JC. The statins-therapeutic diversity in renal disease? Curr Opin Nephrol Hypertens 14: 17-24, 2005.
14. McTaggart F, Buckett L, Davidson R, Holdgate G, McCormick A, Schneck D, Smith G, Warwick M. Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol 87: 28B-32B, 2001.
15. Nakamura T, Obata J, Kimura H, Ohno S, Yoshida Y, Kawachi H, Shimizu F. Blocking angiotensin II ameliorates proteinuria and glomerular lesions in progressive mesangioproliferative glomerulonephritis. Kidney Int 55: 877-889, 1999.
16. Narita I, Border WA, Ketteler M, Noble NA. Nitric oxide mediates immunologic injury to kidney mesangium in experimental glomerulonephritis. Lab Invest 72: 17-24, 1995.
17. Peters H, Border WA, Noble NA. From rats to men: a perspective on dietary L-arginine supplementation in human renal disease. Nephrol Dial Transplant 14: 1640-1650, 1999.
18. Peters H, Martini S, Wang Y, Shimizu F, Kawachi H, Krämer S, Neumayer HH. Selective lymphocyte inhibition by FTY720 slows the progressive course of chronic anti-thy1 glomerulosclerosis. Kidney Int 66: 1434-1443, 2004.
19. Peters H, Noble NA, Border WA. Targeting TGF-beta overexpression in renal disease: maximizing the antifibrotic action of angiotensin II blockade. Kidney Int 54: 1575-1583, 1998.
20. Qin J, Zhang Z, Liu J, Sun L, Hu L, Cooper ME, Cao Z. Effects of the combination of an angiotensin II antagonist with an HMG-CoA reductase inhibitor in experimental diabetes. Kidney Int 64: 565-571, 2003.
21. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med 339: 1448-1456, 1998.
22. Shibata S, Nagase M, Fujita T. Fluvastatin amiliorates podocyte injury in proteinuric rats via modulation of excessive Rho signaling. J Am Soc Nephrol 17: 754-764, 2006.
23. Tonelli M, Keech A, Shepherd J, Sacks F, Tonkin A, Packard C, Pfeffer M, Simes J, Isles C, Furberg C, West M, Craven T, Curhan G. Effect of pravastatin in people with diabetes and chronic kidney disease. J Am Soc Nephrol 16: 3748-3754, 2005.
24. Vidt DG, Harris S, McTaggart F, Ditmarsch M, Sager PT, Sorof JM. Effect of short-term rosuvastatin treatment on estimated glomerular filtration rate. Am J Cardiol 97: 1602-1606, 2006.
25. Wang Y, Kramer S, Loof T, Martini S, Kron S, Kawachi H, Shimizu F, Neumayer HH, Peters H. Stimulation of soluble guanylate cyclase slows progression in anti-thy1-induced chronic glomerulosclerosis. Kidney Int 68: 47-61, 2005.
26. Wang Y, Peters H, Loof T, Martini S, Kron S, Kawachi H, Shimizu F, Krämer S, Neumayer HH. Progression of anti-thy1-induced, chronic glomerulosclerosis is slowed by stimulation of soluble guanylate cyclase (Abstract). J Am Soc Nephrol 15: 488A, 2004.
27. Wolf G, Ritz E. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int 67: 799-812, 2005.
28. Yoshimura A, Inui K, Nemoto T, Uda S, Sugenoya Y, Watanabe S, Yokota N, Taira T, Iwasaki S, Ideura T. Simvastatin suppresses glomerular cell proliferation and macrophage infiltration in rats with mesangial proliferative nephritis. J Am Soc Nephrol 9: 2027-2039, 1998.
29. Zoja C, Corna D, Rottoli D, Cattaneo D, Zanchi C, Tomasoni S, Abbate M, Remuzzi G. Effect of combining ACE inhibitor and statin in severe experimental nephropathy. Kidney Int 61: 1635-1645, 2002.